Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018021892) COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/021892 International Application No.: PCT/KR2017/008239
Publication Date: 01.02.2018 International Filing Date: 31.07.2017
IPC:
A61K 48/00 (2006.01) ,A61K 38/19 (2006.01) ,A61K 39/395 (2006.01) ,A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
에이비온 주식회사 ABION INC. [KR/KR]; 서울시 강남구 개포로34길 5, 창원빌딩 202 (개포동) (Gaepo-dong) #202, Changwon Bldg., 5 Gaepo-ro 34-gil, Gangnam-gu Seoul 06309, KR
서울대학교산학협력단 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION [KR/KR]; 서울시 관악구 관악로 1 (신림동) (Sillim-dong) 1, Gwanak-ro Gwanak-gu, Seoul 08826, KR
Inventors:
신영기 SHIN, Young Kee; KR
김태은 KIM, Tae Eun; KR
홍성열 HONG, Sung Youl; KR
송경 SONG, Kyoung; KR
정헌순 JUNG, Hun Soon; KR
김주석 KIM, Joo Seok; KR
이상윤 LEE, Sang Yun; KR
Agent:
이희숙 LEE, Hee Sook; 서울시 강남구 테헤란로 33길 11, 9층 (역삼동, JS빌딩) (JS Building, Yeoksam-dong) 9th Fl. 11, Teheran-ro 33 gil, Gangnam-gu Seoul 06141, KR
Priority Data:
10-2016-009751629.07.2016KR
Title (EN) COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA
(FR) COMPOSITION POUR LE TRAITEMENT OU LA SENSIBILISATION DE LA MALADIE CANCÉREUSE RÉSISTANT À L'INTERFÉRON BÊTA COMPRENANT DE L'ARNSI DE CFLIP
(KO) cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물
Abstract:
(EN) The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient. The composition of the present invention can be effectively used to develop an anticancer agent or anticancer adjuvant having a new mechanism to promote apoptosis and effectively sensitize cells for treatment, by lowering an expression level of cFLIP proteins in a cancer showing resistance to interferon beta or a cancer becoming resistant to interferon beta.
(FR) La présente invention concerne une composition pour le traitement ou la sensibilisation d'une maladie cancéreuse résistant à l'interféron bêta, comprenant un ARNsi de cFLIP et, plus particulièrement, une composition pharmaceutique pour le traitement d'une maladie cancéreuse résistant à l'interféron bêta, comprenant, en tant que principe actif : (a) un ARNsi se liant de manière complémentaire à l'ARNm d'un gène cFLIP ; et (b) un variant d'interféron bêta humain qui comprend la séquence glycine-asparagine-isoleucine-thréonine-valine (GNITV) en l'extrémité C dans une séquence d'acides aminés d'interféron bêta naturel humain représentée dans la séquence SEQ ID NO : 1 ou dans lequel le 27ème acide aminé arginine a été remplacé par la thréonine ou la sérine, et une composition pour sensibiliser des cellules cancéreuses résistant à l'interféron bêta comprenant l'ARNsi de cFLIP en tant que principe actif. La composition de la présente invention peut être efficacement utilisée pour mettre au point un agent anticancéreux ou un adjuvant anticancéreux présentant un nouveau mécanisme pour promouvoir l'apoptose et sensibiliser efficacement des cellules pour le traitement par l'abaissement d'un niveau d'expression de protéines cFLIP dans un cancer montrant une résistance à l'interféron bêta ou un cancer devenant résistant à l'interféron bêta.
(KO) 본 발명은 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물에 대한 것으로, 보다 상세하게는 (a) cFLIP 유전자의 mRNA에 상보적으로 결합하는 siRNA; 및 (b) 서열번호 1로 표시되는 인간의 천연형 인터페론 베타 아미노산 서열에서 C-말단에 글라이신-아스파라진-이소류신-트레오닌-발린 서열(GNITV)을 포함하거나, 27번째 아르기닌 아미노산이 트레오닌 또는 세린으로 치환된 인간의 인터페론 베타 변이체를 유효성분으로 포함하는 인터페론 베타 저항성 암 질환 치료용 약학적 조성물과 cFLIP siRNA를 유효성분으로 포함하는 인터페론 베타 저항성 암세포 감작용 조성물에 대한 것이다. 본 발명의 조성물은 인터페론 베타에 저항성을 나타내는 암 또는 인터페론 베타에 저항성을 갖게 된 암에서 cFLIP 단백질의 발현 수준을 낮춤으로써 세포사멸을 촉진하고 효과적으로 감작시켜 치료하는 새로운 기작의 항암제 또는 항암 보조제를 개발하는 데 유용하게 이용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)